References
1. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet
Publishing Group; 2016. p. 2783–95.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data
Base report on 53,856 cases of thyroid carcinoma treated in the U.S.,
1985-1995. Cancer. 1998 Dec 15;83(12):2638–48.
3. Toraih EA, Hussein MH, Zerfaoui M, Attia AS, Ellythy AM, Mostafa A,
et al. Site-specific metastasis and survival in papillary thyroid
cancer: The importance of brain and multi-organ disease. Cancers
(Basel). 2021 Apr 1;13(7).
4. Lloyd R, Osamura R, Kloppel G, Rosai J. WHO Classification of Tumours
of Endocrine Organs. 2017.
5. Osborne JR, Kondraciuk JD, Rice SL, Zhou X, Knezevic A, Spratt DE, et
al. Thyroid cancer brain metastasis: Survival and genomic
characteristics of a large tertiary care cohort. Clin Nucl Med. 2019 Jul
1;44(7):544–9.
6. Al-Dhahri SF, Al-Amro AS, Al-Shakwer W, Terkawi AS. Cerebellar mass
as a primary presentation of papillary thyroid carcinoma: case report
and literature review. Head Neck Oncol; 2009. p. 23.
7. Nahed B V., Alvarez-Breckenridge C, Brastianos PK, Shih H, Sloan A,
Ammirati M, et al. Congress of Neurological Surgeons Systematic Review
and Evidence-Based Guidelines on the Role of Surgery in the Management
of Adults with Metastatic Brain Tumors. Oxford University Press; 2019.
p. E152–5.
8. Bunevicius A, Fribance S, Pikis S, Lee JYK, Buch LY, Moran M, et al.
Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain
Metastases: An International, Multicenter Study. Thyroid. 2021 Aug
1;31(8):1244–52.
9. Spitzweg C, Bible KC, Hofbauer LC, Morris JC. Advanced
radioiodine-refractory differentiated thyroid cancer: The sodium iodide
symporter and other emerging therapeutic targets. Lancet Publishing
Group; 2014. p. 830–42.
10. Gild ML, Tsang VHM, Clifton-Bligh RJ, Robinson BG. Multikinase
inhibitors in thyroid cancer: timing of targeted therapy. Nature
Research; 2021. p. 225–34.
11. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R,
et al. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid
Cancer. N Engl J Med. 2015 Feb 12;372(7):621–30.
12. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et
al. Sorafenib in radioactive iodine-refractory, locally advanced or
metastatic diff erentiated thyroid cancer: A randomised, double-blind,
phase 3 trial. Lancet. 2014;384(9940):319–28.
13. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et
al. Long-Term Outcome of 444 Patients with Distant Metastases from
Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of
Radioiodine Therapy. J Clin Endocrinol Metab. 2006 Aug 1;91(8):2892–9.
14. Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, et al. Effects of
Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical
Outcomes in Papillary Thyroid Cancer: A Meta-Analysis. Thyroid. 2017 May
1;27(5):651–60.
15. Ahmed SR, Ball DW. Incidentally discovered medullary thyroid cancer:
Diagnostic strategies and treatment. The Endocrine Society; 2011. p.
1237–45.
16. Dionigi G, Tanda ML, Piantanida E, Uccella S, La Rosa S, Inversini
D, et al. Cohexisting Medullary and Papillary Thyroid Cancer. J Endocr
Surg. 2017;17(2):57.
17. Kazaure HS, Roman SA, Sosa JA. Medullary thyroid microcarcinoma: A
population-level analysis of 310 patients. Cancer. 2012 Feb
1;118(3):620–7.
18. Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R, et
al. Low Prevalence of the Somatic M918T RET Mutation in
Micro-Medullary Thyroid Cancer. Thyroid. 2012 May 1;22(5):476–81.
19. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al.
Revised American thyroid association guidelines for the management of
medullary thyroid carcinoma. Thyroid. 2015 Jun 1;25(6):567–610.
20. Singh A, Butuc R, Lopez R. Metastatic papillary thyroid carcinoma
with absence of tumor focus in thyroid gland. Am J Case Rep.
2013;14:73–5.